TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 1 | 1 | 2 | 8 | 34 | 32 | 29 | 57 | 147 | 51 |
| P | %wins | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/21/08 09:39 | 11/20/08 | BRKR | Bruker Corp | DE | Electr | LabEq | Laboratory Analytical Instrum | Knight William J | MA | O | CFO | P | 19 | 3.73 | 7 | 5 | 9 | 63 | D | -57 | -62 | -72 | -77 | -64 | -18 | -32 | -22 | 3 | 39 | 30 | 28 | 93 | 243 |
11/12/04 09:57 | 11/10/04 | BRKR | Bruker Biosciences Corp | DE | Electr | LabEq | Laboratory Analytical Instrum | Knight William J | MA | O | CFO | P.m | 153 | 3.05 | 0 | 50 | New | 50 | D | -39 | -35 | -40 | -11 | -10 | -1 | -9 | 3 | 13 | 29 | 34 | 29 | 21 | 51 |
9/29/04 16:58 | 9/27/04 | ANIK | Anika Therapeutics Inc | MA | Health | BioPrd | Biological Products, (No Diag | Knight William J | MA | O | CFO | M.d | 19 | 1.01 | 0 | 19 | 65 | 48 | D | 999 | 136 | 62 | -18 | 8 | 7 | 0 | -2 | 1 | 0 | -6 | -31 | -11 | -24 |
5/10/04 11:36 | 5/6/04 | ANIK | Anika Therapeutics Inc | MA | Health | BioPrd | Biological Products, (No Diag | Knight William J | MA | O | CFO | M.d | 29 | 1.02 | 1 | 29 | New | 29 | D | 730 | 304 | 37 | -1 | 9 | 0 | -1 | 0 | -1 | 1 | 47 | 19 | 6 | 82 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |